Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acsnano.3c06667 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HDAC6 inhibitor-loaded brain-targeted nanocarrier-mediated neuroprotection in methamphetamine-driven Parkinson's disease.
Redox Biol
December 2024
Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, 16419, Republic of Korea; School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. Electronic address:
The dynamic equilibrium between acetylation and deacetylation is vital for cellular homeostasis. Parkinson's disease (PD), a neurodegenerative disorder marked by α-synuclein (α-syn) accumulation and dopaminergic neuron loss in the substantia nigra, is associated with a disruption of this balance. Therefore, correcting this imbalance with histone deacetylase (HDAC) inhibitors represents a promising treatment strategy for PD.
View Article and Find Full Text PDFEvaluation of betanin-loaded liposomal nanocarriers in AlCl-induced Alzheimer's disease in rats: Impact on cognitive function, neurodegeneration, and TREM2/ADAM10 pathways.
Arch Pharm (Weinheim)
January 2025
Pharmaceutical Technology Department, Faculty of Pharmacy, Misr International University (MIU), Cairo, Egypt.
Article Synopsis
- - The study investigates the use of BET-loaded liposomal nanocarriers (LPN) as a potential new treatment for Alzheimer’s disease (AD) due to the low effectiveness of betanin (BET) from previous research.
- - In an experiment with 48 male Wistar rats, those treated with BET LPN showed significant improvements in memory and reduced brain degeneration compared to rats receiving other forms of BET or a control treatment.
- - BET LPN treatment not only improved cognitive function but also targeted specific biomarkers and pathways associated with AD, suggesting that it may be a more effective method than traditional oral BET for combating the disease.
Correction: Cytomembrane-mimicking nanocarriers with a scaffold consisting of a CD44-targeted endogenous component for effective asparaginase supramolecule delivery.
Nanoscale
December 2024
Chongqing Research Center for Pharmaceutical Engineering, Chongqing Medical University, Chongqing 400016, China.
Article Synopsis
- The research focuses on developing nanocarriers that mimic cell membranes to enhance the delivery of asparaginase, an enzyme used in cancer treatment.
- These nanocarriers incorporate a scaffold targeted to CD44, a receptor often overexpressed in cancer cells, enabling more effective drug delivery.
- The study demonstrates that these engineered nanocarriers can improve therapeutic outcomes by increasing the concentration of asparaginase at tumor sites while reducing side effects.
Article Synopsis
- The text serves to address an error or issue related to a previously published article identified by its DOI (Digital Object Identifier) number.
- It likely provides clarification or correction on findings, methods, or conclusions presented in the original article.
- The DOI mentioned indicates that the correction is a formal update in the academic record, ensuring that readers can access accurate information.
Correction: Simionescu et al. The Multifaceted Role of Extracellular Vesicles in Glioblastoma: microRNA Nanocarriers for Disease Progression and Gene Therapy. 2021, , 988.
Pharmaceutics
October 2024
Department of Pathophysiology and Pharmacology, Institute of Cellular Biology and Pathology "Nicolae Simionescu" of the Romanian Academy, 8 B.P. Hasdeu Street, 050568 Bucharest, Romania.
In the original publication [...
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!